Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Agenus Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 7.14 · gapped below the open, then crossed back over prior close. High/low 7.15 at 4:00 pm ET, 6.84 at 10:30 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“As part of the collaboration, Zydus LifeSciences agreed to pay to the Company a royalty equal to five percent (5%) of net sales related to the licenses product, subject to certain reductions under certain circumstances.”
$6M relationship
basisAGEN fy2025 · closed 2025-12 $114M
FILING10-K0001193125-26-108632cik 0001098972
“In connection with the divestiture, we entered into a contract manufacturing agreement with Zydus for certain of our manufacturing needs.”
FILING10-K0001193125-26-108632cik 0001098972
“BMS received an exclusive worldwide license to develop, manufacture, and commercialize AGEN1777 and its derivatives.”
FILING10-K0001193125-26-108632cik 0001098972
“Gilead received worldwide exclusive rights to our bispecific antibody, AGEN1423, and the exclusive option to license AGEN1223, a bispecific antibody, and AGEN2373, a monospecific antibody.”
FILING10-K0001193125-26-108632cik 0001098972
“Non-cash royalty revenue related to our agreement with GSK increased $7.6 million, to approximately $108.6 million for the year ended December 31, 2025, from $101.0 million for the year ended December 31, 2024, due to increased net sales of GSK's vaccines containing our QS-21 STIMULON adjuvant.”
FILING10-K0001193125-26-108632cik 0001098972
“Pursuant to our collaboration agreement with Incyte, we had exclusively licensed to Incyte monospecific antibodies targeting GITR, OX40, TIM-3 and LAG-3, as well as an additional undisclosed target.”
FILING10-K0001193125-26-108632cik 0001098972
“Pursuant to our collaboration and license agreement with Merck, we exclusively licensed to Merck a monospecific antibody targeting ILT4 (MK-4830), which Merck advanced in a Phase 2 clinical trial.”
FILING10-K0001193125-26-108632cik 0001098972
“In November 2019, we entered into a license agreement with UroGen, granting them an exclusive, worldwide license (not including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions) to develop, manufacture, and commercialize zalifrelimab for the treatment of cancers of the urinary tract via intravesical delivery.”
FILING10-K0001193125-26-108632cik 0001098972
“The Registration Statement includes prospectuses covering the offer, issuance and sale of up to 20.6 million shares of our common stock from time to time in "at-the-market offerings" pursuant to an At Market Issuance Sales Agreement (the "Sales Agreement") with B. Riley Securities, Inc. as our sales agent.”
FILING10-K0001193125-26-108632cik 0001098972
“In May 2024, we entered into the Agenus Agreement to support BOT/BAL clinical development.”
FILING10-K0000886163-26-000006cik 0000886163disclosed by LGND
“We regularly maintain cash balances at third-party financial institutions, such as Silicon Valley Bank ("SVB"), in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance limit.”
FILING10-K0001193125-26-108632cik 0001098972
“In May 2024, we, and certain wholly-owned subsidiaries, entered into a Purchase and Sale Agreement (the "Ligand Purchase Agreement") with Ligand Pharmaceuticals Incorporated ("Ligand") for the sale to Ligand of (i) 31.875% of the development, regulatory and commercial milestone payments we were then eligible to receive under our agreements with BMS, UroGen, Gilead, Merck and Incyte, (the "Covered License Agreements") (ii) 18.75% of the royalties we receive under the Covered License Agreements; and (iii) a 2.625% synthetic royalty on worldwide net sales of botensilimab and balstilimab (collectively the "Purchased Assets").”
FILING10-K0001193125-26-108632cik 0001098972
“In May 2025 we terminated a license and collaboration agreement with Betta Pharmaceuticals covering the license of balstilimab and zalifrelimab in the territory of greater China, which could result in a dispute or litigation.”
FILING10-K0001193125-26-108632cik 0001098972
“Pursuant to the terms of the XOMA Royalty Purchase Agreement, XOMA US purchased 33% of all future royalties and 10% of all future milestone payments that we were then entitled to receive from Incyte and Merck, net of certain of our obligations to a third party.”
FILING10-K0001193125-26-108632cik 0001098972
Watchlist prices, news filtered to it, and its next report on your desk.
Agenus Inc has 4 disclosed suppliers and 10 disclosed customers. Each one is named in an SEC filing, either Agenus Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
AGEN (Agenus Inc) has 4 disclosed suppliers and 10 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: LGND +0.76%, in healthcare.